Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Arrests GM, Others Of Maker Of Tainted Human Rabies Vaccine

This article was originally published in PharmAsia News

Executive Summary

Chinese authorities arrested three Dalian Jingang-Andi Bio-products employees, including two senior executives, for alleged fraud in producing a human rabies vaccine containing a banned ingredient. Arrested were the company's general manager, his deputy and a purchasing agent. China's State FDA requested the arrests after the firm was found to have deliberately included nucleic acid in the anti-rabies compound over a five-month period last year. Authorities also ordered confiscated the company's earnings from the 360,200 doses of the vaccine that have been recalled. (Click here for more

You may also be interested in...



Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Falling Sales Force New Priorities At Roche

The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.

Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics

CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel